BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime Sells 10,000 Shares of Stock

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 10,000 shares of the firm’s stock in a transaction dated Thursday, March 16th. The shares were sold at an average price of $91.69, for a total transaction of $916,900.00. Following the transaction, the chief executive officer now owns 211,364 shares of the company’s stock, valued at approximately $19,379,965.16. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Jean Jacques Bienaime also recently made the following trade(s):

  • On Friday, March 10th, Jean Jacques Bienaime sold 11,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.59, for a total transaction of $996,490.00.
  • On Thursday, January 26th, Jean Jacques Bienaime sold 10,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $84.22, for a total transaction of $842,200.00.
  • On Wednesday, January 11th, Jean Jacques Bienaime sold 8,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $90.58, for a total transaction of $724,640.00.
  • On Monday, January 9th, Jean Jacques Bienaime sold 8,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $88.49, for a total transaction of $707,920.00.
  • On Friday, December 30th, Jean Jacques Bienaime sold 8,000 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $83.60, for a total transaction of $668,800.00.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down 1.14% during mid-day trading on Monday, hitting $89.86. 477,945 shares of the company traded hands. The company’s market capitalization is $15.53 billion. The company’s 50-day moving average price is $90.49 and its 200 day moving average price is $88.80. BioMarin Pharmaceutical Inc. has a one year low of $73.45 and a one year high of $102.49.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, February 23rd. The company reported ($0.53) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by $0.15. The firm had revenue of $300 million for the quarter, compared to the consensus estimate of $296.54 million. BioMarin Pharmaceutical had a negative return on equity of 8.54% and a negative net margin of 46.22%. The business’s revenue for the quarter was up 31.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.39 earnings per share. On average, analysts anticipate that BioMarin Pharmaceutical Inc. will post ($0.95) earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

var userip;Your IP Address: document.write(userip);

BMRN has been the subject of several research reports. Gabelli initiated coverage on shares of BioMarin Pharmaceutical in a research report on Thursday, December 8th. They set a “buy” rating and a $109.00 price objective for the company. Instinet initiated coverage on shares of BioMarin Pharmaceutical in a research report on Wednesday, March 1st. They set a “neutral” rating and a $93.00 price objective for the company. Vetr lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $91.77 price objective for the company. in a research report on Monday, November 28th. Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a research report on Wednesday, December 28th. Finally, Robert W. Baird set a $115.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Monday, January 9th. Nine research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $110.49.

A number of hedge funds have recently made changes to their positions in the company. Cornerstone Advisors Inc. boosted its stake in shares of BioMarin Pharmaceutical by 22.0% in the third quarter. Cornerstone Advisors Inc. now owns 1,159 shares of the company’s stock valued at $107,000 after buying an additional 209 shares in the last quarter. Independent Portfolio Consultants Inc. purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $121,000. Toronto Dominion Bank boosted its stake in shares of BioMarin Pharmaceutical by 57.8% in the third quarter. Toronto Dominion Bank now owns 1,401 shares of the company’s stock valued at $130,000 after buying an additional 513 shares in the last quarter. Ardsley Advisory Partners purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $231,000. Finally, Morningstar Investment Services LLC purchased a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at $268,000. 97.78% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

5 Day Chart for NASDAQ:BMRN

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Fuel Shortage in Venezuela Growing Worse
Fuel Shortage in Venezuela Growing Worse
FedEx Comes Up Short on Earnings
FedEx Comes Up Short on Earnings
Brazil Looks to Calm Fears Over Export and Sale of Meat
Brazil Looks to Calm Fears Over Export and Sale of Meat
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Oil Prices Drop to Low of Three Months on Rig Count
Oil Prices Drop to Low of Three Months on Rig Count


Leave a Reply

© 2006-2017 Ticker Report. Google+.